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Ovarian cancer (OC) is the most lethal gynecology cancer in the world. Although 
carboplatin is one of the major drugs used to treat OC, resistance to carboplatin remains a 
major barrier to successful treatment. To date, the mechanisms of carboplatin resistance 
are still poorly understood. The purpose of this study is to use the novel validation-based 
insertional mutagenesis (VBIM) technique to identify carboplatin resistance gene in 
A2780 OC cells. A2780 cells were infected with VBIM virus to cause the overexpression 
of drug resistance genes, then were further selected under carboplatin treatment. Targeted 
gene was then identified by using VBIM specific primers. In a preliminary screen, we 
identified the novel carboplatin resistance gene 1 (NCR1). Overexpression of NCR1 
increased carboplatin resistance in A2780 OC cells, while knocking it down with shRNA 
had the opposite effect. In an attempt to investigate the molecular mechanism that 
underlying NCR1-mediated carboplatin resistance, we found that NCR1 is a potential NF-
κB activator. In summary, we conclude that using a novel VBIM technique, we 
discovered a previously unknown carboplatin resistance gene NCR1, which may mediate 
drug resistance via NF-κB signaling pathway. This study is of extreme importance by 
identifying a potential novel therapeutic target NCR1 in carboplatin resistance. 
Development of small chemical inhibitors targeting NCR1 could ultimately lead to novel 
therapeutic approach for ovarian cancer treatment. 
 
 
 
 
 
